
    
      Primary objective is to demonstrate a better clinical response profile of novel
      levodopa/carbidopa formulation vs. the reference formulation of levodopa/carbidopa in
      patients with Parkinson's Disease as judged by motor performance and to describe
      pharmacokinetic profile for the novel formulation compared to the reference.
    
  